Donation

The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.

 

Patient Handbook for Multiple Myeloma

Updated in April 2026, the IMF Patient Handbook offers an overview of myeloma, including its precursor conditions,…

Order Print
Order Digital
Understanding Myeloma Vocabulary
The International Myeloma Foundation provides this glossary that defines commonly used multiple myeloma-related terms
Order Print
Order Digital
Understanding Your Test Results
This booklet explains the tests used to diagnose, monitor, and assess myeloma.
Order Print
Order Digital
Request a Free IMF Info Pack

Full of our informative publications, including our Patient Handbook and selections from the popular Understanding Series, the Info Pack…

Order Print
Understanding Dexamethasone
This booklet discusses dexamethasone, a synthetic steroid that is one of the most frequently used medica­tions in the treatment of myeloma.
Order Print
Order Digital
Understanding Clinical Trials in Myeloma
This publication discusses what myeloma patients should consider if enrolling in a clinical trial.
Order Print
Order Digital
Understanding ABECMA® (idecabtagene vicleucel)
Immunotherapy with Abecma® (idecabtagene vicleucel or “ide-cel” for short) is FDA-approved for the treatment of relapsed refractory multiple myeloma…
Order Print
Order Digital
Understanding BLENREP® (belantamab mafodotin-blmf)
This booklet discusses Blenrep® (belantamab mafodotin-blmf), an antibody-drug conjugate (ADC) that is a combination of a monoclonal antibody and a…
Order Print
Order Digital
Understanding CARVYKTI® (ciltacabtagene autoleucel)

Carvykti® (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of patients…

Order Print
Order Digital
Understanding CELMoDs (Cereblon E3 Ligase Modulatory Drugs)
This booklet serves as an introduction to cereblon E3 ligase modulatory drugs (CELMoDs), a new class of medications currently being studied in…
Order Digital
Order Print
Understanding DARZALEX® and DARZALEX FASPRO®

This booklet discusses Darzalex® and Darzalex Faspro® -- two different formulations of an equally effective monoclonal antibody that target the…

Order Print
Order Digital
Understanding ELREXFIO® (elranatamab-bcmm)
Elrexfio™ (elranatamab-bcmm) is a B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.
Order Print
Order Digital
Understanding EMPLICITI® (elotuzumab)

Empliciti® (elotuzumab) is the first immunostimulatory monoclonal antibody approved for the treatment of myeloma. Empliciti enlists immune system…

Order Print
Order Digital
Understanding Fatigue
Patients with myeloma may experience fatigue caused by the disease itself or by treatment for myeloma, as well as by other medical problems or their…
Order Print
Order Digital
Understanding KYPROLIS® (carfilzomib) for Injection
This publication discusses the use of Kyprolis (carfilzomib)— a proteasome inhibitor—for the treatment of myeloma.
Order Print
Order Digital
Understanding LYNOZYFIC™ (linvoseltamab-gcpt)
In July 2025, the FDA approved the use of Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with relapsed/refractory multiple…
Order Print
Order Digital
Understanding MGUS and Smoldering Myeloma
This publication covers monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Order Print
Order Digital
Understanding Neuropathy in Myeloma
This publication discusses peripheral neuropathy, which can be a complication of multiple myeloma or its treatments.
Order Print
Order Digital
Understanding NINLARO® (ixazomib)
There are two Ninlaro-based treatment options to be considered by patients who can benefit from an all-oral drug regimen.
Order Print
Order Digital
Understanding POMALYST® (pomalidomide) capsules
This publication discusses the use of Pomalyst (pomalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
Order Print
Order Digital
Understanding REVLIMID® (lenalidomide)
This publication discusses the use of Revlimid (lenalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
Order Print
Order Digital
Understanding SARCLISA® (isatuximab-irfc)
The Understanding SARCLISA® (isatuximab-irfc) booklet discusses a novel anti-CD38 monoclonal antibody that is approved for patients with relapsed and…
Order Print
Order Digital
Understanding Stem Cell Transplant in Myeloma
This publication is for myeloma patients in the U.S. who are considering undergoing an autologous stem cell transplant (ASCT).
Order Print
Order Digital
Understanding TALVEY® (talquetamab-tgvs)
Talvey (talquetamab-tgvs) is indicated for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior…
Order Print
Order Digital
Understanding TECVAYLI® (teclistamab-cqyv)
Tecvayli® (also known as teclistamab-cqyv, its generic drug name) is an immunotherapy that enhances a patient’s own immune system to attack myeloma…
Order Print
Order Digital
Understanding THALOMID® (thalimdomide)
This publication discusses the use of Thalomid (Thalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
Order Print
Order Digital
Understanding the Immune System in Myeloma
This publication discusses the effects of multiple myeloma on the immune system.
Order Print
Order Digital
Understanding the Isa-VRd Regimen for Newly Diagnosed Myeloma
Isa-VRd is an effective “quadruplet” (4-drug) regimen that combines medicines from 4 drug classes: the monoclonal antibody Sarclisa® (isatuximab-irfc…
Order Print
Order Digital
Understanding the VRd Regimen for Newly Diagnosed Myeloma
This booklet discusses Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone as treatment for newly diagnosed myeloma.
Order Print
Order Digital
Understanding Treatment of Myeloma Bone Disease
This booklet will familiarize you with myeloma-related bone disease (MBD) and the therapies available to prevent or treat it.
Order Print
Order Digital
Understanding Treatment of Myeloma-Induced Vertebral Compression Fractures
This publication discusses how myeloma patients can manage vertebral compression fractures.
Order Print
Order Digital
Understanding VELCADE® (bortezomib) for Injection
This publication discusses the use of Velcade (bortezomib)—a proteasome inhibitor—for the treatment of myeloma.
Order Print
Order Digital
Understanding XPOVIO® (selinexor)
This booklet discusses Xpovio (selinexor) for the treatment of multiple myeloma.
Order Print
Order Digital

with support from:

Johnson & Johnson, Sanofi, and Pfizer.

Give Where Most Needed

Learn More